Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devorah Segal

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Neurosurgical Focus|May 10, 2022
Management and surgical outcomes of dystrophic scoliosis in neurofibromatosis type 1: a systematic reviewSean N Neifert, Hammad A Khan, David B Kurland, et al.
Pediatric Dermatology|November 8, 2024
Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and SelumetinibCarli D Needle, Lu Yin, Trevor K Young, et al.
Neuroimage|January 5, 2010
Diffusion tensor anisotropy in the cingulate gyrus in schizophreniaDevorah Segal, M Mehmet Haznedar, Erin A Hazlett, et al.
Neurogenetics|May 2, 2019
A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activityDavid B Beck, T Subramanian, S Vijayalingam, et al.
Annals of Neurology|January 31, 2017
Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppressionHeather E Olson, McKenna Kelly, Christopher M LaCoursiere, et al.
Human Molecular Genetics|January 10, 2020
Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein traffickingRobert Behne, Julian Teinert, Miriam Wimmer, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Neurosurgical Focus|May 10, 2022
Management and surgical outcomes of dystrophic scoliosis in neurofibromatosis type 1: a systematic reviewSean N Neifert, Hammad A Khan, David B Kurland, et al.
Pediatric Dermatology|November 8, 2024
Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and SelumetinibCarli D Needle, Lu Yin, Trevor K Young, et al.
Neuroimage|January 5, 2010
Diffusion tensor anisotropy in the cingulate gyrus in schizophreniaDevorah Segal, M Mehmet Haznedar, Erin A Hazlett, et al.
Neurogenetics|May 2, 2019
A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activityDavid B Beck, T Subramanian, S Vijayalingam, et al.
Annals of Neurology|January 31, 2017
Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppressionHeather E Olson, McKenna Kelly, Christopher M LaCoursiere, et al.
Human Molecular Genetics|January 10, 2020
Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein traffickingRobert Behne, Julian Teinert, Miriam Wimmer, et al.
Neuro-Oncology|December 19, 2024
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialKarsten Nysom, Lindsay B Kilburn, Sarah E S Leary, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Pageof 4